D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$728M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$625M |
| 3 |
Merck
MRK
|
+$498M |
| 4 |
Bank of America
BAC
|
+$487M |
| 5 |
Fortinet
FTNT
|
+$321M |
Top Sells
| 1 |
Tesla
TSLA
|
+$696M |
| 2 |
Adobe
ADBE
|
+$610M |
| 3 |
Accenture
ACN
|
+$518M |
| 4 |
Microsoft
MSFT
|
+$495M |
| 5 |
Broadcom
AVGO
|
+$471M |
Sector Composition
| 1 | Technology | 22.95% |
| 2 | Consumer Discretionary | 14.11% |
| 3 | Healthcare | 10.4% |
| 4 | Financials | 9.83% |
| 5 | Industrials | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
GE Vernova
GEV
$175B
| $27.3M | 0.02% |
107,218
-602,720
| -85% | -$154M |
|
477
Lowe's Companies
LOW
$149B
| $27.3M | 0.02% |
100,660
-5,212
| -5% | -$1.41M |
|
478
Selective Insurance
SIGI
$4.75B
| $27.2M | 0.02% |
291,970
+193,216
| +196% | +$18M |
|
479
AutoZone
AZO
$71.1B
| $27.2M | 0.02% |
8,635
-13,617
| -61% | -$42.9M |
|
480
PVH
PVH
$3.93B
| $27.1M | 0.02% |
269,033
+82,912
| +45% | +$8.36M |
|
481
Regions Financial
RF
$24.1B
| $27.1M | 0.02% |
1,162,101
+361,209
| +45% | +$8.43M |
|
|
ITCI
482
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $27M | 0.02% |
368,680
-211,679
| -36% | -$15.5M |
|
483
Pediatrix Medical
MD
$1.44B
| $27M | 0.02% |
2,325,503
-138,357
| -6% | -$1.6M |
|
484
Industrial Select Sector SPDR Fund
XLI
$23.2B
| $26.9M | 0.02% |
198,573
+18,573
| +10% | +$2.52M |
|
485
Ulta Beauty
ULTA
$23.1B
| $26.9M | 0.02% |
69,022
-82,236
| -54% | -$32M |
|
486
Cooper Companies
COO
$13.5B
| $26.8M | 0.02% |
243,149
-116,869
| -32% | -$12.9M |
|
487
Alaska Air
ALK
$7.22B
| $26.7M | 0.02% |
+590,202
| New | +$26.7M |
|
488
Southern Company
SO
$101B
| $26.7M | 0.02% |
295,842
+19,517
| +7% | +$1.76M |
|
489
Amdocs
DOX
$9.23B
| $26.6M | 0.02% |
303,564
-243,992
| -45% | -$21.3M |
|
490
Light & Wonder
LNW
$7.43B
| $26.4M | 0.02% |
291,304
+101,449
| +53% | +$9.2M |
|
491
Royalty Pharma
RPRX
$15.6B
| $26.4M | 0.02% |
932,340
+898,728
| +2,674% | +$25.4M |
|
492
Warby Parker
WRBY
$3.29B
| $26.3M | 0.02% |
1,610,059
+680,928
| +73% | +$11.1M |
|
|
AACT
493
Ares Acquisition Corporation II
AACT
$706M
| $26.1M | 0.02% |
2,413,500
+900,000
| +59% | +$9.75M |
|
494
NETSCOUT
NTCT
$1.8B
| $26.1M | 0.02% |
1,199,559
-76,167
| -6% | -$1.66M |
|
495
Expeditors International
EXPD
$16.5B
| $26M | 0.02% |
197,554
-211,844
| -52% | -$27.8M |
|
496
Goldman Sachs
GS
$233B
| $25.8M | 0.02% |
52,199
-283,739
| -84% | -$140M |
|
|
EQC
497
DELISTED
Equity Commonwealth
EQC
| $25.8M | 0.02% |
1,297,789
+136,001
| +12% | +$2.71M |
|
498
Advanced Drainage Systems
WMS
$11B
| $25.8M | 0.02% |
164,114
+28,138
| +21% | +$4.42M |
|
499
B2Gold
BTG
$5.74B
| $25.8M | 0.02% |
8,354,027
+7,415,283
| +790% | +$22.9M |
|
500
Travere Therapeutics
TVTX
$2.43B
| $25.7M | 0.02% |
1,840,069
+306,997
| +20% | +$4.29M |
|